𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Presence of infective Epstein-Barr virus in the urine of patients with infectious mononucleosis

✍ Scribed by Zvi Landau; Raz Gross; Anka Sanilevich; Adam Friedmann; Stella Mitrani-Rosenbaum

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
456 KB
Volume
44
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The presence of Epstein‐Barr virus (EBV) in the blood and urine of 20 patients with infectious mononucleosis (IM) was investigated together with the clinical course of the disease, and in 9 patients up to 2–7 months after recovery. EBV DNA, analyzed by the polymerase chain reaction (PCR), was detected in the blood of all 20 patients from the first sample obtained and detected between 3 to 42 days from the beginning of symptoms and up to 2–3 months after recovery. In the urine, EBV DNA was detected in 15 out of 16 (93%) patients in the first sample obtained and detected between 3 to 50 days during the clinical course of the disease. In four patients EBV DNA was detected in the urine up to 3 months after full recovery. Seventeen out of 26 (65%) urine samples including 3 which were obtained 2–7 months after recovery infected B cells as assessed by PCR. Nine out of 12 (75%) urine samples tested induced Epstein‐Barr nuclear antigen (EBNA) in the infected B‐cell line. In addition to the persistence of EBV in the blood of IM patients, these studies show for the first time the presence of infective EBV in the urine during the clinical course of the disease and up to 7 months after full clinical recovery. © 1994 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Infectious mononucleosis patients tempor
Infectious mononucleosis patients temporarily recognize a unique, cross-reactive epitope of Epstein-Barr virus nuclear antigen-1
✍ Micah T. McClain; Erin C. Rapp; John B. Harley; Judith A. James 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

## Abstract The spectrum of antibodies against Epstein‐Barr virus nuclear antigen‐1 (EBNA‐1) in patients with a recent history of infectious mononucleosis and nonaffected EBV‐positive individuals has been characterized by epitope mapping. Sera were evaluated for antibodies to all unique maximally o

Epstein–Barr virus BZLF1 gene promoter v
Epstein–Barr virus BZLF1 gene promoter variants in pediatric patients with acute infectious mononucleosis: Its comparison with pediatric lymphomas
✍ Mario Alejandro Lorenzetti; Marina Inés Gutiérrez; Jaime Altcheh; Guillermo Mosc 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB

## Abstract Epstein–Barr virus genotypes can be distinguished by polymorphic variations in the genes encoding EBNA2, 3A, 3B, and 3C. The immediate early gene BZLF1 plays a key role in modulating the switch from latency to lytic replication and therefore enabling viral propagation. The aim of this s

Neurological complications of acute and
Neurological complications of acute and persistent Epstein-Barr virus infection in paediatric patients
✍ Martin Häusler; Vincent Thomas Ramaekers; Martin Doenges; Klaus Schweizer; Klaus 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 373 KB

Neurological complications of Epstein-Barr virus (EBV) have been reported almost exclusively in the course of acute primary infections. The role of EBV in paediatric neurological disease was investigated prospectively over a 2-year period, searching for acute primary, chronic, and reactivated EBV in